heart failure with preserved ejection fraction
Conditions
Interventions
test group:Spironolactone
control group:placebo
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. essential hypertension with aged 50 to 80 years old, diagnostic criteria refered to ; 2. echocardiographic signs of LVH (LV mass index (LVMI) was >125 g/m2 for men and >110 g/m2 for women); 3. LVEF>=50%; 4. Voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. heart failure with reduced ejection fraction and stage C or D of heart failure with preserved ejection fraction; 2. organic heart disease (coronary artery disease, valvular heart disease, cardiomyopathy, congenital heart disease); 3. secondary hypertension; 4. documented contraindication or allergy to aldosterone antagonist therapy; 5. patient received aldosterone antagonist therapy in recent three months; 6. electrolyte disturbance; 7. severe kidney dysfunction: eGFR<30ml/min/1.73m2; 8. severe liver dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular diastolic function (TDI: E/E’); | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical composite end point (stage C or D of heart failure with preserved heart failure, hospitalization due to heart failure and cardiac death);LVMI;LVEF; | — |
Countries
China
Contacts
Public ContactChang-qian Wang
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed